Xydalba (dalbavancin) is the first antibiotic to provide a full course of iv therapy for acute bacterial skin and skin structure infections in a single dose.
Further informationView dalbavancin drug record
Dalbavancin is available as a powder for concentrate to be made up into a solution for infusion providing 20mg per ml.
The recommended adult dose is a single iv infusion of 1.5g given over 30 minutes or a single infusion of 1g followed by a 500mg dose one week later. Dalbavancin is not recommended in children and adolescents under 18 years of age.
Dalbavancin is a bactericidal lipoglycopeptide which demonstrates in vitro activity against Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus.
The most commonly reported adverse effects with dalbavancin in clinical trials were headache, nausea and diarrhoea.